Searched for
MORAIYA AHMEDABAD
Zydus Lifesciences gets USFDA nod to market chronic heart failure treatment drugZydus Lifesciences Ltd has received final approval from the USFDA to market its generic Sacubitril and Valsartan tablets for treating chron...- Zydus Lifesciences gets USFDA nod to sell generic anti-epileptic medicationZydus Lifesciences has received approval from the US FDA to market Lacosamide Tablets, a generic anti-epileptic medication used to treat pa...
- Zydus Lifesciences gets USFDA nod for generic acne-treating drugZydus Lifesciences received final approval from the US health regulator for its generic antibiotic Minocycline Hydrochloride extended-relea...
- Zydus Life receives final USFDA approval for insomnia drugThe approval granted by the US Food and Drug Administration (USFDA) is to market Triazolam tablets of strengths 0.125 mg and 0.25 mg, the c...
- Zydus Cadila gets USFDA nod for prostate condition treatment drugThe drug is used to treat symptoms of Benign Prostatic Hyperplasia (BPH) -- also called prostate gland enlargement.
- Zydus Cadila gets USFDA nod for sedative injectionThe approval from USFDA is to market Dexmedetomidine Hydrochloride injection 200 mcg (base)/ 2 ML and 100 mcg (base)/ ML single dose virals...
- Cadila gets USFDA nod for generic drug to treat Parkinson'sThe Ahmedabad-based firm also received final approval from the USFDA to market Nitrofurantoin Capsules USP, used for treating acute uncompl...
- Zydus gets USFDA nod for seizure, migraine drugZydus Cadila has more than 170 approvals and has so far filed over 310 abbreviated new drug applications (ANDAs) since it commenced filings...
- Zydus Cadila gets USFDA nod for Mycophenolate MofetilThe approval is for Mycophenolate Mofetil injection of strength 500mg/vial, the company said in a BSE filing.
- USFDA clears marketing of Zydus Cadila anti-hypertension drugThe company has received final nod from the US Food and Drug Administration (USFDA) to market the drug in the strengths of 4 mg, 8 mg, 16 m...
- Zydus Cadila gets USFDA nod to market anti-dementia tablets"Zydus Cadila has received final approval from the USFDA to market Memantine Hydrochloride tablets USP, 5mg and 10mg," Cadila Healthcare sa...
- Cadila receives audit closure reportThe Moraiya manufacturing plant had completed the USFDA audit from February 6th to 15th 2017 with Zero 483 observations, the company said.
- Zydus Cadila gets USFDA nod for anti-viral drugAcylovir for injection USP caters to the anti-viral segment, the company said adding that it will be produced at the group's formulations m...
- Cadila Healthcare surges 7% on receiving USFDA approval for levofloxacin injectionThe stock climbed 7.18 per cent to hit a high of Rs 504.8 on BSE.
- Cadila Healthcare gets EIR for Ahmedabad plant from USFDA"The company's Oral Solid Dosage drug manufacturing plant located at SEZ, Ahmedabad has received an Establishment Inspection Report (EIR) f...
- Cadila gets EIR from USFDA for Changodar facilityLast month, Cadila Healthcare had received Establishment Inspection Report (EIR) from the US health regulator for its manufacturing facilit...
- Cadila gets US FDA warning for violating standards at Moraiya and Ahmedabad plantsThe company said its Moraiya and Ahmedabad facilities have been cited in the letter, and it is working on responding to the FDA concerns re...
- USFDA revoke's warning to Cadila HealthcareThe US drug regulator has revoked its earlier warning letter to Ahmedabad-based Cadila Healthcare Ltd.
- Transformers and Rectifiers lists at 69% premiumTransformers and Rectifiers listed at Rs 790, premium of Rs 325 or 69.89 per cent against the issue price of Rs 465 per share on the Nation...
- Transformers & Rectifiers IPO subscribed 65.63 timesThe initial public offer of Transformers and Rectifiers (India) closed for subscription on Wednesday. The issue was subscribed 65.63 times,...
Load More
